Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Generic Drugs
ScinoPharm Taiwan launches more cancer treatment active pharmaceutical ingredients in U.S.
February 14th, 2007
Oncological API (active pharmaceutical ingredient) specialist ScinoPharm announced the launch of ondansetron hydrochloride (HCl) API in the U.S. after one of its clients recently received an abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA). This product launch came only a few months after the successful introduction of another cancer-treatment ingredient, paclitaxel, from ScinoPharm. "Ondansetron HCl is ScinoPharm's sixth API product marketed in the U.S.," said Jo Shen, ScinoPharm president and CEO. Currently, out of the 22 DMFs the company has registered with the FDA, seven of them are oncological...
Source: Medical Patent Law Weekly (2007-02-14)
|
